|
Originally published In Press as doi:10.1074/jbc.M512391200 on May 12, 2006
J. Biol. Chem., Vol. 281, Issue 38, 28122-28130, September 22, 2006
N-terminally Truncated WT1 Protein with Oncogenic Properties Overexpressed in Leukemia*
Anwar Hossain 1,
Molly Nixon ,
Macus T. Kuo , and
Grady F. Saunders
From the
Departments of Biochemistry and Molecular Biology and Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77054
WT1 was originally identified as an inactivated gene in Wilms tumor, a childhood kidney cancer. Alternative splicing of the WT1 transcript generates four major protein isoforms, each having different functional properties. Here we characterized a short transcript originating from a second promoter located within intron 1 of WT1. This 2.3-kb sWT1 transcript encodes a protein of 3537 kDa that retains intact DNA-binding and transactivation domains but lacks the 147 amino acids at the N terminus required for transcriptional repression. We found sWT1 to be a more potent transcriptional activator than WT1 for cyclin E and insulin-like growth factor 1 receptor promoters, which are normally repressed by WT1. The expression patterns of the sWT1 and WT1 transcripts differed slightly in various organs; we found sWT1 protein in tissue samples from adult testis and fetal kidney, with low-level expression in adult kidney as well. The sWT1 transcript, but not the full-length transcript, was over-expressed in the leukemia samples tested. sWT1-specific small interfering RNA retarded the proliferation of leukemia cell line K562 in vitro. Finally, sWT1 cooperated with Ras in transforming primary fibroblasts in vitro. Further studies are needed to clarify the oncogenic behavior of this isoform and to determine the mechanism underlying its up-regulation in leukemia and other forms of cancer.
Received for publication, November 18, 2005
, and in revised form, May 8, 2006.
* This work was supported by National Institutes of Health Grants CA34936 and CA16672. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the Gen-BankTM/EBI Data Bank with accession number(s) DQ537939
[GenBank]
.
Deceased.
1 To whom correspondence should be addressed: Dept. of Molecular Pathology, Unit 951, The University of Texas M. D. Anderson Cancer Ctr., 7435 Fannin St., Houston, TX 77054. Tel.: 713-834-6079; Fax: 713-834-6084; E-mail: ahossain{at}mdanderson.org.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. W. Brown, F. Power, B. Moore, A. K. Charles, and K. T.A. Malik
Frequency and Timing of Loss of Imprinting at 11p13 and 11p15 in Wilms' Tumor Development
Mol. Cancer Res.,
July 1, 2008;
6(7):
1114 - 1123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Morrison, M. K.H. Kim, W. Berkofsky-Fessler, and J. D. Licht
WT1 Induction of Mitogen-Activated Protein Kinase Phosphatase 3 Represents a Novel Mechanism of Growth Suppression
Mol. Cancer Res.,
July 1, 2008;
6(7):
1225 - 1231.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Hancock, K. W. Brown, K. Moorwood, H. Moon, C. Holmgren, S. H. Mardikar, A. R. Dallosso, E. Klenova, D. Loukinov, R. Ohlsson, et al.
A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis
Hum. Mol. Genet.,
February 1, 2007;
16(3):
343 - 354.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|